Postoperative reparalysis after rocuronium following nebulized epinephrine

Canadian Journal of Anaesthesia

Volumn 44, Issue 3, 1997, Pages 321-324

  Arndt, George A ^a   Gerry, Tim ^a   White, Patricia ^a  

^a University of Wisconsin Health   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; ALFENTANIL; ANESTHETIC AGENT; ATRACURIUM; ATROPINE; EDROPHONIUM; ETOMIDATE; GLYCOPYRRONIUM BROMIDE; HALOTHANE; MIDAZOLAM; MUSCLE RELAXANT AGENT; NEOSTIGMINE; NITROUS OXIDE; ROCURONIUM; VECURONIUM;

ARTICLE; BRONCHOSCOPY; CASE REPORT; CHILD; DOSE RESPONSE; DRUG METABOLISM; FEMALE; HUMAN; INHALATIONAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MUSCLE RELAXATION; MUSCLE WEAKNESS; NEBULIZER; NEUROMUSCULAR BLOCKING; NEUROMUSCULAR FUNCTION; PARALYSIS; PEDIATRIC ANESTHESIA; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL;

EID: 0030791529     PISSN: 0832610X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03015373     Document Type: Article

References (15)

1. Booij LHDJ, Knape HTA. The neuromuscular blocking effect of ORG 9426. A new intermediately-acting steroidal non-depolarising muscle relaxant in man. Anaesthesia 1991; 46: 341-3.
2. Wierda JMKH, De Wit APM, Kuizenga K, Agoston S. Clinical observations on the neuromuscular blocking action of ORG 9426, a new steroidal non-depolarizing agent. Br J Anaesth 1990; 64: 521-3.
3. Mirakhur RK, McCoy EP. The new relaxants. Current Opinion in Anaesthesiology 1994; 7: 365-9.
4. Woelfel SK, Brandom BW, Cook DR, Sarner JB. Effects of bolus administration of ORG-9426 in children during nitrous oxide - halothane anesthesia. Anesthesiology 1992; 76: 939-42.
5. O'Kelly B, Fiset P, Meistelman C, Ecoffey C. Pharmacokinetics of rocuronium bromide in paediatric patients. Eur J Anaesthesiol 1994; 11(Suppl): 57-8.
6. Wierda JMKH, Proost JH, Schiere S, Hommes FDM. Pharmacokinetics and pharmacokinetic/dynamic relationship of rocuronium bromide in humans. Eur J Anaesthesiol 1994; 11(Suppl): 66-74.
7. Bevan DR. Rocuronium bromide and organ function. Eur J Anaesthesiol 1994; 11(Suppl): 87-91.
8. Cooper RA, Mirakhur RK, Wierda JMKH, Maddineni VR. Pharmacokinetics of rocuronium bromide in patients with and without renal failure. Eur J Anaesthesiol 1995; 12(Suppl): 43-4.
9. van den Broek L, Proost JH, Wierda JMKH. Early and late reversibility of rocuronium bromide. Eur J Anaesthesiol 1994; 11(Suppl): 128-32.
10. Magorian T, Wood P, Caldwell J, Fisher D, et al. The pharmacokinetics and neuromuscular effects of rocuronium bromide in patients with liver disease. Anesth Analg 1995; 80: 754-9.
11. Khalil M, D'Honneur G, Duvaldestin P, Slavov V, De Hys C, Gomeni R. Pharmacokinetics and pharmacodynamics of rocuronium in patients with cirrhosis. Anesthesiology 1994; 80: 1241-7.
12. Harrison GG. Death attributable to anaesthesia. A 10-year survey (1967-1976). Br J Anaesth 1978; 50: 1041-6.
13. Viby-Mogensen J, Jørgensen BC, Ørding H. Residual curarization in the recovery room. Anesthesiology 1979; 50: 539-41.
14. Miller R. How should residual neuromuscular blockade be detected? (Editorial) Anesthesiology 1989; 70: 379-80.
15. Naguib M, Abdulatif M, Al-Ghamdi A. Dose-response relationships for edrophonium and neostigmine antagonism of rocuronium bromide (ORG 9426)-induced neuromuscular blockade. Anesthesiology 1993: 79: 739-45.